The FDA granted fast-track status to Genzyme's alemtuzumab as a treatment for relapsing-remitting multiple sclerosis. The drug might rival Biogen Idec's MS treatments if it receives approval.
Published in Brief:
|President/Chief Executive Officer||
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Director, Payer Marketing||
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
|Chief Medical Officer, Texas Children's Health Plan||
Cejka Executive Search for Texas Childre's Health Plan